Trial Profile
Prevention of hepatocarcinogenesis after combinatoin therapy with daclatasvir and asunaprevir : A pilot study in usefulness of a small amount of Peg-interferon
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2017
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
- 01 Mar 2017 Status changed from recruiting to discontinued.
- 08 Oct 2015 New trial record